Teva Shares Climb On Profit Beat, $700 Million Cost Plan, Biopharma Pivot MomentumBenzinga • 05/07/25
Teva Pharmaceutical Industries Limited (TEVA) Q1 2025 Earnings Call TranscriptSeeking Alpha • 05/07/25
Teva Surges On Profit Guidance Boost Despite A Mixed First-Quarter ReportInvestors Business Daily • 05/07/25
Teva Reports Ninth Consecutive Quarter of Growth in Q1 2025 With Key Innovative Medicines Growing ~40%; 2025 Profit Outlook ImprovedGlobeNewsWire • 05/07/25
Why Is Israel-Based Generic Drug Focused Teva Pharmaceutical Stock Trading Higher On Monday?Benzinga • 05/05/25
What Analyst Projections for Key Metrics Reveal About Teva Pharmaceutical Industries (TEVA) Q1 EarningsZacks Investment Research • 05/05/25
Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI™ (ustekinumab-aekn) with Stelara® (ustekinumab)GlobeNewsWire • 05/05/25
Trump Tariff Sell-Off: 3 Superb Stocks That Make for No-Brainer Buys Right NowThe Motley Fool • 04/21/25
5 of the Safest Stocks Billionaire Money Managers Bought Ahead of Wall Street's Historic VolatilityThe Motley Fool • 04/13/25
Trump's Tariffs Circle Pharma Industry: Who It Affects And How It May Play OutSeeking Alpha • 04/09/25
Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug ImportsInvestors Business Daily • 04/09/25
Teva Announces FDA Filing Acceptance for AJOVY® (fremanezumab) in Pediatric Episodic Migraine PreventionGlobeNewsWire • 04/07/25
New Data Strengthens Teva's Schizophrenia Portfolio, Including Phase 3 SOLARIS Trial Survey Results Demonstrating Patient and Healthcare Professional Satisfaction with TEV-'749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting InjectableGlobeNewsWire • 03/31/25
These Are My 3 Worst-Performing Stocks So Far in 2025 -- and the One I'm Buying More of NowThe Motley Fool • 03/28/25
Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at 8 a.m. ET on May 7, 2025GlobeNewsWire • 03/27/25
Billionaire Stanley Druckenmiller Jettisoned Shares of Palantir and Nvidia, and Is Piling Into 3 High-Profile Turnaround StocksThe Motley Fool • 03/24/25